Connect with us

Life Sciences

PacBio Announces New Nanobind Extraction Kits to Enable High-Throughput Workflows with Revio and Sequel Systems

Kits Combine the Power of HiFi Sequencing and Nanobind Technology to Optimize Sample Preparation Workflows for High Volume Customers PacBio, a leading…

Published

on

This article was originally published by AITHORITY
PacBio Announces New Nanobind Extraction Kits to Enable High-Throughput Workflows with Revio and Sequel Systems

Kits Combine the Power of HiFi Sequencing and Nanobind Technology to Optimize Sample Preparation Workflows for High Volume Customers

PacBio, a leading developer of high-quality, highly accurate sequencing solutions, announced the availability of its new high-throughput (HT) Nanobind DNA Extraction kits, another key product from the highly valuable Circulomics acquisition. These kits are designed to enable researchers to extract high-quality DNA from a wide range of samples in a high-throughput setting, with a simple and rapid protocol that is compatible with platforms from leading automation providers.

AiThority Interview Insights: AiThority Interview with Kyle Wong, Chief Strategy Officer at Emplifi

Using scripts now available through some of PacBio’s Compatible partners, the HT Nanobind DNA Extraction kits, along with PacBio’s long-read sequencing technology, researchers will have the tools to complete accurate genome assemblies, identify structural variants, and explore complex biological systems in extraordinary detail in high-throughput labs. This represents another step towards PacBio’s commitment to further address the needs of high-throughput customers, who began taking delivery of their first Revio sequencing systems during the first quarter of 2023.

“The availability of the HT Nanobind DNA Extraction kits represents a major advancement in DNA extraction technology, with significant benefits for researchers in genomics, microbiology, and many other fields,” said Jeff Eidel, Chief Commercial Officer at PacBio. “By enabling fast, reliable, and scalable DNA extraction, we believe these kits will accelerate research across a wide range of applications. The HT Nanobind DNA Extraction kits offer a solution to the potential bottleneck of sample preparation. As we’ve shown with the Sample Preparation Kit 3.0 that was launched in July 2022, we will continue to focus on scaling and automating every step of the long-read sequencing workflow.”

Read More about AiThority InterviewAiThority Interview with Jon Zimmerman, Chief Executive Officer at Holon Solutions

The HT Nanobind DNA Extraction kits are based on proprietary Nanobind disks, which are composed of a porous, silica-based material that efficiently binds and releases high molecular weight DNA. The disks can be used for the extraction of DNA from diverse sample types, including blood, cell, and tissue samples. With this technology, researchers can extract high-quality DNA in less than two hours, with minimal sample input and without the use of harmful chemicals or mechanical homogenization.

 Latest AiThority Interview Insights : AiThority Interview with Malcolm Koh, Director, CX Practice at Zendesk

 [To share your insights with us, please write to sghosh@martechseries.com] 

The post PacBio Announces New Nanobind Extraction Kits to Enable High-Throughput Workflows with Revio and Sequel Systems appeared first on AiThority.

Life Sciences

Wittiest stocks:: Avalo Therapeutics Inc (NASDAQ:AVTX 0.00%), Nokia Corp ADR (NYSE:NOK 0.90%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Markets

Spellbinding stocks: LumiraDx Limited (NASDAQ:LMDX 4.62%), Transocean Ltd (NYSE:RIG -2.67%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner

The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….

Continue Reading

Trending